Guo Yue-Lu, Dong Li-Li, Gao Li, Xu Yuan-Yuan, Ding Yi, Wang Li-Li, Jing Yu, Bo Jian, Zhou Min-Hang, Cao Ting-Ting, Yu Li
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1370-3.
Diffuse large B cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL), characterized by great heterogeneity in clinical manifestations and molecular genetics. This study was aimed to explore the clinical significance of applying multiplex PCR to detect BCL2/IGH and BCL6/IGH fusion genes in DLBCL. Multiplex PCR was used to detect bone marrow samples from 80 cases of DLBCL. The results showed that 12 patients (15%) carried BCL2/IGH or BCL6/IGH fusion genes, BCL2/IGH was found in 6 patients (7.5%), and BCL6/IGH in another 6 patients (7.5%). The patients with different molecular markers displayed different clinical features and outcomes. It is concluded that multiple PCR is rapid and accurate method to identify gene abnormalities in DLBCL, but further studying a quantitative or semi-quantitative assay for the expression of fusion genes is needed.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL），其临床表现和分子遗传学具有高度异质性。本研究旨在探讨应用多重PCR检测DLBCL中BCL2/IGH和BCL6/IGH融合基因的临床意义。采用多重PCR检测80例DLBCL患者的骨髓样本。结果显示，12例患者（15%）携带BCL2/IGH或BCL6/IGH融合基因，其中6例患者（7.5%）检测到BCL2/IGH，另外6例患者（7.5%）检测到BCL6/IGH。具有不同分子标志物的患者表现出不同的临床特征和预后。结论是，多重PCR是识别DLBCL基因异常的快速准确方法，但需要进一步研究融合基因表达的定量或半定量检测方法。
